Clinical trials: Rosai Dorfman Disease
Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG)
Mirdametinib in Histiocytic Disorders
The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.
- Conditions
- Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG), Rosai-Dorfman Disease (RDD), Histiocytic Disorders
- Trial name
- NCT06153173
- Testing
- Mirdametinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Histiocytosis, Langerhans Cell Histiocytosis
Histiocytic Disorder Follow-up Study
The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific…
- Conditions
- Histiocytosis, Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai Dorfman Disease
- Trial name
- NCT05915208
- Where
- United States
- Volunteers
- 6,000 people
- Sponsor
- University of Alabama at Birmingham
Rare Histiocytic Disorders (RHDs), Erdheim-Chester Disease (ECD)
International Rare Histiocytic Disorders Registry (IRHDR)
The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more organs by non-LCH histiocytes. They can range from localized disease that resolves spontaneously, to progressive disseminated forms that…
- Conditions
- Rare Histiocytic Disorders (RHDs), Erdheim-Chester Disease (ECD), Rosai-Dorfman Disease (RDD), Xanthogranuloma Family (XG)
- Trial name
- IRHDR (NCT02285582)
- Testing
- Registry study
- Where
- 15 sites in United States, Argentina and 7 more
- Volunteers
- 400 people
- Sponsor
- The Hospital for Sick Children
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment.
- Conditions
- Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease
- Trial name
- NACHO-COBI (NCT04079179)
- Testing
- Cobimetinib
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- Carl Allen